Technical Data Sheet

InVivoSIM anti-human CD20 (Rituximab Biosimilar)



Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bxcell.com/terms-and-conditions/.

Lot Specific Information

Lot Number:Lot Specific*Volume:Lot Specific*

Concentration: Lot Specific* (generally 4 to 11 mg/ml) *

Total Protein: Lot Specific*

Product Information

Catalog Number:SIM0008Clone:RituximabIsotype:human IgG1

Recommended Isotype Control(s):InVivoPlus human IgG1 isotype control
Recommended Dilution Buffer:
InVivoPure pH 7.0 Dilution Buffer

Immunogen: Human lymphoblastoid cell line SB

Flow Cytometry

Reported Applications:ELISA
Western Blot

Formulation:

PBS, pH 7.0

Contains no stabilizers or preservatives

Endotoxin: <1EU/mg (<0.001EU/μg)

Determined by LAL gel clotting assay

Sterility: 0.2 μM filtered

Production: Purified from cell culture supernatant

 Purification:
 Protein A

 Aggregation:
 <5%</th>

 Determined by DLS

150 D

Molecular Weight: 150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative,

Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative,

Description

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Rituximab making it ideal for research use. This Rituximab biosimilar reacts with human CD20. CD20 is a B cell-specific 33-37 kDa transmembrane protein which is also known as B-lymphocyte antigen, B1, and Bp35. CD20 plays roles in intracellular calcium regulation and B cell activation and is critical for an optimal B cell immune response against T-independent antigens. CD20 is first expressed after the induction of CD19 together with IgM during the pre-B to immature B cell transition in the bone marrow. It's expression then increases during maturation with almost all mature B cells expressing some level of CD20. However, CD20 is not expressed by plasma blasts or plasma cells. CD20 is expressed by most B cell neoplasms, and is useful in diagnosing B cell lymphomas and leukemia's. Many anti-CD20 monoclonal antibodies are currently being used to successfully treat leukemia's, lymphomas, and various autoimmune diseases. Rituximab has depleting activity and mediates ADCC and CDC of CD20⁺ cells. This results in the elimination of B cells from the body.

Shelf-life and Storage

Store at the stock concentration at 4°C. Do not freeze.

All Bio X Cell antibodies have a guaranteed shelf-life of one year from the date of customer receipt when stored as recommended. It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at bxcell.com/fags.

Bio X Cell, Inc.

bxcell.com

1.866.787.3444

customerservice@bxcell.com

^{*}This information will be noted on the certificate of analysis that ships with this product.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bxcell.com/product/invivosim-anti-human-cd20-rituximab-biosimilar/#references or scan the QR code below.



Bio X Cell, Inc.

bxcell.com

1.866.787.3444